Gitelman syndrome is caused by inactivating mutations of the gene that encodes the renal sodium chloride co-transporter (NCC, SLC12A3) resulting in hypokalemia, hypomagnesemia, hypocalciuria and a metabolic alkalosis. Renal salt-wasting commonly provokes mild hypotension. The paucity of previous kidney transplants from donors with known tubulopathies suggests that such conditions may be considered contraindications to donation.
Introduction
Gitelman syndrome is an autosomal recessive disorder caused by inactivating mutations of the gene that encodes the sodium chloride co-transporter (NCC, SLC12A3) located on the apical surface of distal convoluted tubular cells in the distal nephron. Those affected develop the biochemical phenotype of hypokalemia, hypomagnesemia, hypocalciuria and a metabolic alkalosis. Blood pressure tends to be low as a result of renal salt wasting. It is one of the commonest inherited tubular disorders with an estimated incidence of 1:40000 1 .
Renal transplantation from donors with Gitelman syndrome has only been reported on two previous occasions 2, 3 and in each case it was inadvertent. This suggests that tubulopathies, even with the usually mild phenotype of Gitelman syndrome, are considered a contraindication to donation by the transplant community. There is presently no guidance on the use of these organs for kidney donation.
However, rather than being detrimental, it is plausible that the presence of a salt-wasting tubulopathy like Gitelman syndrome in a donor organ may promote normotension and also mitigate against the adverse salt-retaining effects of calcineurin inhibitors (CNIs) which are mediated by increased NCC activity 4 ; thereby conferring improved graft survival.
We report the planned transplant of a kidney from a living donor with Gitelman syndrome. 4 
Case report
The recipient was a 76-year old man with end-stage renal disease due to histologicallyproven hypertensive nephropathy who was maintained on peritoneal dialysis. Blood pressure control was sub-optimal despite triple anti-hypertensive therapy (once daily bisoprolol 5mg, amlodipine 10mg, doxazosin 4mg) with a blood pressure of 172/88 mmHg at the time of transplantation.
The donor was a 67-year old male, diagnosed with Gitelman syndrome 20 years earlier after incidental detection of asymptomatic hypokalemia. He had been prescribed amiloride 20mg twice daily to maintain a normal serum potassium concentration. His blood pressure prior to donation was 119/75 mmHg. He was genotyped using the TUBMASTR multiplex PCR Even though mild hypokalaemia was present from day 1, the potassium concentration did not fall below 3.0 mmEq/L and did not require supplementation ( Supplementary Figure 1b The development of hyponatremia was in the sameperiod. Only two cases of hyponatremia in patients with Gitelman syndrome have been published before; one associated with volume expansion, the other with hypovolemia 6 . Interestingly, the case previously reported by Hu et al. also received long-term sodium supplementation, probably for volume expansion 2 . It is tempting to ascribe hyponatremia in our patient to a low intravascular volume, with secondary ADH secretion causing free water retention and an inappropriately high urinary osmolality. However, the patient's hypertension, low serum urate concentration and unresponsiveness to sodium or mineralocorticoid weigh against this. Another possibility is that this was a phenomenon mimicking the high volume state seen in thiazide-induced hyponatremia. The timeframe (10 days) is similar to that reported for thiazide-induced hyponatremia 7 , as is the hypochloraemia 8 .The underlying mechanism of thiazide induced hyponatraemia is unclear, but recent evidence implicates prostaglandin E2 (PGE2) 8 , which can increase collecting duct permeability to water independent of ADH. Increased urinary PGE2, which is usually associated with variants of Bartter syndrome, may also be raised in Gitelman syndrome 9 . PGE2 directly stimulates juxtaglomerular cells to release renin, and activate the renin-angiotensin-aldosterone system, causing many of the electrolyte abnormalities.
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This raises the intriguing possibility that this hyponatremia might be responsive to nonsteroidal anti-inflammatory drugs (NSAIDs). Indeed, NSAIDs are effective in ameliorating electrolyte abnormalities 10 Our patient had a marked improvement in his blood pressure resulting in his antihypertensive requirement being halved. Hypertension is common post renal transplantation and is (in part at least) mediated by an increase of NCC activity caused by CNIs 4 .
The hypertensive phenotype of tacrolimus (hypertension, hyperkalaemia, hypercalciuria and metabolic acidosis), closely resembles the phenotype of the Mendelian disorder Familial Hyperkalaemic Hypertension (caused by mutations of WNK1, WNK4, CUL3 and KLHL3) and is due to overactivity of NCC. This is caused by dysregulation of its regulatory serine/threonine kinases, WNK1, 3, 4 and SPAK 4 . Furthermore, thiazide diuretics, pharmacological inhibitors of NCC, reverse tacrolimus-induced hypertension 4 .
Given that Gitelman syndrome is the genetic equivalent of chronic thiazide diuretic administration (genetic and pharmacologic inhibition of NCC respectively) it is biologically plausible that transplanting a kidney from a donor with Gitelman syndrome will be beneficial for blood pressure control and, indeed, this is the experience of the two previously reported cases.
The incomplete resolution of hypertension in this patient may be explained by extra-renal elements of his pre-transplant hypertension as well as the systemic and renal vasoconstriction and reduced vasodilatation that may be caused by CNIs 13 . There is one report of the late 9 development of hypertension in patients with Gitelman syndrome 14 . It was speculated that this may be due to chronic activation of the renin-angiotensin-aldosterone system. As the donor is normotensive, this seems an unlikely explanation for the recipient's incomplete resolution of his hypertension; chronic hypertension is highly prevalent in transplant recipients 15 .
Furthermore, the hypocalciuria transferred to the recipient may theoretically protect against CNI-induced osteopenia, which occurs in association with CNI-induced hypercalciuria 16 .
Both Gitelman syndrome 17 and thiazide administration 18 are associated with increased bone mineral density. However, this effect may not be wholly due to renal calcium absorption; osteoblasts express NCC, and pharmacologic inhibition of NCC in vitro causes osteoblast differentiation, and mineralised nodule formation 19 . It may be that genetic inhibition of osteoblast, rather than renal, NCC function is the cause of increased BMD in Gitelman syndrome, in which case this theoretical advantage would not be conferred to the transplant recipient.
This case demonstrates that Gitelman syndrome need not preclude living donation and, indeed, may offer some advantages. It remains to be seen whether these theoretical advantages translate into better long term graft outcomes. Biochemical abnormalities may be transferred but can be anticipated and treated, as can volume expansion or depletion.
Whether hyponatraemia is a frequent complication and what its aetiology is remain unanswered questions. 
